KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients 

KIMS Hospitals is one of the first centres in the country to implement the sensing-enabled, closed-loop system for Parkinson’s disease. This technology integrates real-time brain-sensing capabilities to automatically adjust stimulation levels based on neural activity.  

The system enables real-time brain-sensing capabilities and delivers a more personalised neuromodulation therapy experience. 

According to Towards Healthcare, the deep brain stimulation devices market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.34 billion in 2026 to approximately USD 5.04 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Growth is driven by the rising prevalence of neurological disorders, which require advanced treatment options, including technological and minimally invasive procedures adopted by healthcare researchers. This is supported by increasing investments in research and development. 

From Conventional DBS to Adaptive Closed-Loop Technology 

Traditional Deep Brain Stimulation (DBS) has helped reduce tremors, rigidity, and slowness of movement in people living with Parkinson’s disease. It delivers constant electrical stimulation, and DBS continuously monitors local field potentials in the beta frequency range and modulates therapy accordingly. 

DBS represents a significant evolution of this system, which continuously monitors brain activity, specifically local field potentials in the beta frequency range, and adjusts stimulation levels in real time. 

Clinical Advantages of Adaptive DBS 

Director & Lead Consultant in Neurology and Head of the Parkinson’s Disease and Movement Disorder Programme at KIMS Hospitals, Dr. Guruprasad Hosurkar, stated the benefits of adaptive DBS. 

First, the system significantly reduces the need for patients to manually adjust device settings because it responds automatically to symptom changes. Second, stimulation usage may decrease by nearly 50%, where patients could experience extended battery life and potentially lower long-term replacement costs. Lastly, the device limits unnecessary excess stimulation, which may reduce the risk of stimulation-related side effects in the surrounding brain tissue. 

A recent report by Towards Healthcare highlights that the deep brain stimulation devices market is witnessing growth due to the increasing prevalence of neurological disorders and the acceptance of neuromodulation therapies, and is expanding due to the integration of artificial intelligence and machine learning into device functionality, which is designed for personalised treatment plans. 

North America dominates the deep-brain stimulation devices market, holding a significant share and growing at a rapid pace. While the Asia-Pacific region is emerging as the fastest-growing area for deep brain stimulation devices, this region's growth is expected to be faster than the global average, reflecting the region's commitment to improving healthcare access and quality.